| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/MOH.0000000000000026 |
| P8608 | Fatcat ID | release_xzvejkl5cvcnlo2lbuqp2v4hlq |
| P3181 | OpenCitations bibliographic resource ID | 3052569 |
| P932 | PMC publication ID | 4131840 |
| P698 | PubMed publication ID | 24468835 |
| P2093 | author name string | Samantha M. Jaglowski | |
| Steven M. Devine | |||
| P2860 | cites work | Novel treatment concepts for graft-versus-host disease | Q26860139 |
| Dendritic cells and the control of immunity | Q27860918 | ||
| Thalidomide for treatment of patients with chronic graft-versus-host disease. | Q31599290 | ||
| Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone | Q33342878 | ||
| Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease | Q33445669 | ||
| Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. | Q33608255 | ||
| Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease | Q33649332 | ||
| High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. | Q33806054 | ||
| Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation | Q33910076 | ||
| Advances in graft-versus-host disease biology and therapy | Q34031916 | ||
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
| Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease | Q34640239 | ||
| Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial | Q34998580 | ||
| Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies | Q35083281 | ||
| Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networ | Q35148420 | ||
| Treatment of chronic graft-versus-host disease: Past, present and future | Q35524687 | ||
| Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease | Q68882743 | ||
| Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors | Q70051817 | ||
| Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial | Q72537942 | ||
| Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease | Q73266667 | ||
| IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade | Q73497705 | ||
| Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors | Q74296144 | ||
| Response as an end point in treatment trials for acute GVHD | Q83399715 | ||
| Graft-versus-host disease | Q83468020 | ||
| Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation | Q35750957 | ||
| Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR | Q35848083 | ||
| Mesenchymal stromal cells: a new tool against graft-versus-host disease? | Q35848391 | ||
| Rituximab for steroid-refractory chronic graft-versus-host disease | Q35848933 | ||
| Regulation of acute graft-versus-host disease by microRNA-155. | Q36010229 | ||
| Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity | Q36014986 | ||
| First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
| Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation | Q36212400 | ||
| Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning | Q36319726 | ||
| Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow | Q36342244 | ||
| Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors | Q36951734 | ||
| Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future | Q36980277 | ||
| Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 | ||
| Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial | Q37113099 | ||
| Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes | Q37143633 | ||
| Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. | Q37201939 | ||
| Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat | Q37238884 | ||
| Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation | Q37247581 | ||
| Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease | Q37291611 | ||
| Recognizing and managing chronic graft-versus-host disease | Q37346706 | ||
| Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease | Q37348628 | ||
| Mouse models of graft-versus-host disease: advances and limitations | Q37874011 | ||
| Are we making progress in GVHD prophylaxis and treatment? | Q38066876 | ||
| One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation | Q39139747 | ||
| A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. | Q41942186 | ||
| Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation | Q42539543 | ||
| Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation | Q42539545 | ||
| A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis | Q43183770 | ||
| Duration of immunosuppressive treatment for chronic graft-versus-host disease | Q43590716 | ||
| Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | Q43636158 | ||
| Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation | Q44107506 | ||
| Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 | ||
| Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial | Q44892383 | ||
| A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation | Q45010717 | ||
| Imatinib for refractory chronic graft-versus-host disease with fibrotic features. | Q46031486 | ||
| Hematopoietic-cell transplantation at 50. | Q48546980 | ||
| Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
| Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius | Q56525543 | ||
| Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials | Q68124653 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 141-7 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Current Opinion in Hematology | Q15757961 |
| P1476 | title | Graft-versus-host disease: why have we not made more progress? | |
| P478 | volume | 21 |
| Q40085103 | Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells |
| Q93143232 | B Lymphocytes Are the Target of Mesenchymal Stem Cells Immunoregulatory Effect in a Murine Graft-versus-Host Disease Model |
| Q26764759 | Biomaterials and host versus graft response: a short review |
| Q50989345 | Cataract after allogeneic hematopoietic stem cell transplantation in childhood. |
| Q55397395 | Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease. |
| Q35495340 | Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. |
| Q87285223 | Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD |
| Q40777375 | Graft-versus-host Disease After Intestinal or Multivisceral Transplantation: A Scandinavian Single-center Experience. |
| Q27004303 | Graft-versus-host disease affecting oral cavity. A review |
| Q39096609 | Hsp90 inhibition ameliorates CD4(+) T cell-mediated acute Graft versus Host disease in mice |
| Q88758943 | Medication nonadherence to immunosuppressants after adult allogeneic haematopoietic stem cell transplantation: a multicentre cross-sectional study |
| Q87559422 | Neuromuscular complications after hematopoietic stem cell transplantation |
| Q40551837 | Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. |
| Q47200642 | Peri-Transplant RBC Transfusion is Associated with Increased Risk of GvHD after Allogeneic Stem Cell Transplantation |
| Q43627667 | Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease |
| Q95648233 | Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level |
| Q38696262 | Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis |
Search more.